RISING TIDES
Observations from the IMC Research Process


Global Pharma Knocking on China’s Door

 

From Boston to Beijing: Cheaper labor and fewer regulations are shifting drug discovery from the US to China.

  • In-licensing deals are booming. Multinational pharmaceutical companies are increasingly tapping Chinese biotechs for innovative R&D. Over 30% of large pharma in-licensed drugs are now from China. The latest: Pfizer licensing an oncology asset from 3SBio for up to $6B in milestones.
  • China is now R&D-advantaged. Clinical trials are 30-50% cheaper and faster with new policies in April 2025, cutting approval timelines to <20 weeks.
  • Momentum continues to build. Recent out-licensing deals by China biotechs like Akeso/Summit for $5B, Biokin Pharma for $8B, Shanghai Argo for up to $4B, and 3SBio for $6B.

 

This report is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. IMC or its clients may hold positions in securities mentioned; the mention of specific companies does not imply endorsement or a recommendation. Past trends do not guarantee future results.

X

Please fill out the form below to request the strategy fact sheet.

Name(Required)
(i.e. john@mycompany.com)
Which strategy are you requesting?(Required)

Your email and website usage data (via cookies) will solely be used for internal purposes. We will not contact you for marketing or share your information with third parties, except as required by law. You can manage cookies through your browser, and we implement reasonable security measures to protect your data.